Female Contraception - Pipeline Review, H2 2016 - Key Players are Addex Therapeutics, Agile Therapeutics, ANI Pharmaceuticals, Bayer AG, Evofem, Orbis Biosciences & Teva Pharmaceutical Industries - Research and Markets

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Female Contraception - Pipeline Review, H2 2016" report to their offering.

Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).

This report provides comprehensive information on the therapeutic development for Female Contraception, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Contraception and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Female Contraception Overview
3. Therapeutics Development
4. Pipeline Products for Female Contraception - Overview
5. Pipeline Products for Female Contraception - Comparative Analysis
6. Female Contraception - Therapeutics under Development by Companies
7. Female Contraception - Therapeutics under Investigation by Universities/Institutes
8. Female Contraception - Pipeline Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Female Contraception - Products under Development by Companies
13. Female Contraception - Products under Investigation by Universities/Institutes
14. Female Contraception - Companies Involved in Therapeutics Development
    

Companies Mentioned

• Addex Therapeutics Ltd
• Agile Therapeutics Inc
• ANI Pharmaceuticals Inc
• Bayer AG
• Evofem Inc
• Hervana Ltd
• Mithra Pharmaceuticals SA
• Orbis Biosciences Inc
• Teva Pharmaceutical Industries Ltd
• Viramal Ltd
  

For more information about this report visit http://www.researchandmarkets.com/research/ttk8w9/female